Food and Drug Administration
Center for Drug Evaluation and Research
Holiday Inn, The Ballrooms, Two Montgomery Village Avenue, Gaithersburg, MD.

Summary Minutes of the Pediatrics Subcommittee of the Anti-Infective Drugs Advisory Committee

June 11 & 12, 2003

AntiInfective Drugs Advisory Committee Members Present

Mary Glode, M.D. Steven Ebert, Pharm. D.

Consultants

Patricia Chesney, M.D.	Mark Hudak, M.D.	Benjamin Wilfond M.D.
Robert Nelson, M.D., Ph.D.	David Danford, M.D.	Richard Gorman, M.D., FAAP
Norman Fost, M.D.	Judith O'Fallon, Ph.D.	Don Mattison, M.D.
Susan Fuchs, M.D.	Thomas B. Newman, M.D.	Alan R. Fleischman, M.D.
David Stevenson, M.D.	William Oh, M.D.	Kevin Smith, Ph.D.
Rebecca Flynn O'Brien, M.D.	Benjamin Wilfond, M.D.	Michael Aschner, Ph.D.
John Freeman, M.D.	Stanley Ip, M.D.	Joseph Lau, M.D.

Guests

Marshalyn Yeargin-Allsopp, M.D.	Connie Schomann, R.N.,	Susan Sheridan,

FDA Participants

Dianne Murphy, M.D.	Robert Justice, M.D.	Susan Cummins, M.D.
Min Chen, M.S.	Solomon Iyasu, M.D.	

These summary minutes for the June 11 & 12, 2003 meeting of the Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee were approved on June 20, 2003.

I certify that I attended the June 11 & 12, 2003 meeting of the Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee, and that these minutes accurately reflect what transpired.

_____ _____

Thomas H. Perez, M.P.H., R.Ph.
Executive Secretary

Patricia Chesney, M.D.
Chair

The Pediatric Subcommittee of the AntiInfective Drugs Advisory Committee, of the Food and Drug Administration, Center for Drug Evaluation and Research met June 11 & 12, 2003 at the Holiday Inn, The Ballrooms, Two Montgomery Village Avenue, Gaithersburg, MD.

On June 11, 2003 the Subcommittee discussed the current epidemiology and therapeutic interventions relevant to hyperbilirubinemia in the term and near-term newborn. On June 12, 2003 at 3:45 p.m. the agency reported to the subcommittee on Adverse Event Reporting as mandated in Section 17 of the Best Pharmaceuticals for Children Act. The products discussed during this portion of the meeting included Zoloft® (sertraline) Pfizer Inc., and Ditropan® (oxybutynin) Alza Corp., with an interim update provided on Lipitor® (atorvastatin) Pfizer Inc., and Zocor® (simvastatin) Merck & Co. Inc.

The Subcommittee and invited guests received a briefing document from the FDA in preparation for this meeting.

There were approximately 100 persons present at the meeting on June 11. The meeting was called to order at 8:35 a.m. by the Chair, Joan Chesney, M.D. The Subcommittee members and discussants introduced themselves. Thomas H. Perez, Executive Secretary of the Pediatric Subcommittee of the AntiInfective Drugs Advisory Committee read the Meeting Statement. A welcome and opening comments were provided by Dianne Murphy, M.D., Director, Office of Counterterrorism and Pediatric Drug Development.

Presentations began at 8:50 a.m. and proceeded as follows.

Historical Background & Selected Recent Research Findings	Tom Newman, M.D., M.P.H., UCSF School of Medicine
Agency for Healthcare Research & Quality Report	Joseph Lau, M.D., Stanley Ip, M.D., & Rebecca O'Brien, M.D Tufts New England Medical Center

At 10:50 the subcommittee began a brief discussion of the prior presentations and continued on with their discussion of question 1. After a 15 minute break the following presentations began at 11:15 a.m.

Phototherapy	William Oh, M.D., Brown University
Outpatient Phototherapy	Connie Schomann, R.N., Medstar Visiting Nurse Assoc.

At 12:15 the subcommittee broke for lunch, and reconvened at 1:05 p.m., with the following presentations.

A Parent's Perspective	Sue Sheridan, President Parents of Infants and Children with Kernicterus
Kernicterus Surveillance	Marshallyn Yeargin-Allsop, M.D. Centers for Disease Control and Prevention
Metalloporphyrin Heme Oxygenase Inhibitors	David Stevenson, M.D., Stanford University

After a 15 minute break the subcommittee reconvened at 2:55 p.m. to hear from the following participants scheduled for the open public hearing portion of the meeting.

Attallah Kappas, M.D.,Rockefeller University
Vinod K. Bhutani, M.D., University of Pennsylvania
Martin J. Hatlie, J.D., President, Partnership for Patient Safety
Duane Alexander, M.D., Director NICH & HD, NIH
Andrew S. Moosa, M.D., Director of Newborn Nurseries & Infant ICU
Jerold F. Lucey, M.D., Professor of Peds. & Neonatology at the University of Vermont College of Medicine
Murray Goldstein, D.O., UCP Research & Educational Foundation
Timos Valaes, M.D.

The final presentation of the day was moved up on the agenda and began at 4:15 p.m.
Ethical Issues by Robert Nelson, M.D., Ph.D., The Children's Hospital of Philadelphia

The Subcommittee began its discussion of the remaining questions 2, 3 & 4 at 4:30 p.m. Dr. Joan Chesney, as Chair, provided the meetings final and closing comments. The meeting was adjourned at 6:30 p.m.

The meeting on June 12 was called to order at 3:45 p.m. by the Chair, Joan Chesney, M.D. The Subcommittee members and discussants introduced themselves. Thomas H. Perez, Executive Secretary of the Pediatric Subcommittee of the AntiInfective Drugs Advisory Committee read the Meeting Statement. There were approximately 30 persons present. Dr. Iyasu gave the meetings only presentation.

Adverse Event Reports – as per Section 17, Best Pharmaceuticals for Children Act	Solomon Iyasu, M.D. Division of Pediatric Drug Development

There were no participants for the Open Public Hearing. The chair, Dr. Joan Chesney provided the final comments, and the meeting was adjourned at 4:40 p.m.

On June 11, the Subcommittee discussed the following questions to which no votes were requested or taken. The discussion will be made available through the meeting transcripts and placed on the web in approximately three weeks. Transcripts may be accessed at: www.fda.gov/ohrms/dockets/ac/acmenu.htm.

Questions to the Subcommittee

QUESTION 1

Discuss the current controversies in the diagnosis and management of hyperbilirubinemia.

QUESTION 2

In the context of current medical practice, including phototherapy, should drugs be developed for an earlier intervention to prevent hyperbilirubinemia in newborn infants?

In answering this question, please discuss the following:

•Your understanding of the relationship between bilirubin toxicity and neurodevelopmental outcome;

•How you define the population at high risk for complications of hyperbilirubinemia;

•The intervention sequence (e.g., more screening, additional monitoring and assessments, phototherapy, hydration, pharmacotherapy, cessation of breast feeding, changes in infant nutrition, home nursing visit, etc.) and Why?

QUESTION 3

Assuming that hyperbilirubinemia only requires therapeutic intervention with phototherapy approximately 3 to 5 percent of the time, what safety information would you require from a sponsor for a new molecular entity before it could be introduced into the newborn population?

QUESTION 4

In today's healthcare setting, does the benefit of drug therapy to prevent hyperbilirubinemia in the newborn population as a whole outweigh the risk to individual newborns, the majority of whom require no intervention?